EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation : vimarsana.com

ROCKLAND, Mass., October 10, 2023--EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new analyses from the MAVENCLAD® (cladribine) tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. Additional data include two real-world evi

Related Keywords

Germany , United Kingdom , Italy , Australia , Switzerland , United States , Milan , Lombardia , Massachusetts , Canada , Rockland , Ontario , America , Merck Kga , Alexander Kulla , Drug Administration , Serono , European Union , Serono Inc , Merck Kgaa , Nflz Scores , Senior Vice President , Medical Unit Head Neurology , Latin America , Graft Versus Host Disease With Blood Transfusions , Concomitant Medication , Specific Populations , Prescribing Information , Emd Serono , Erck Kgaa , Avenclad , Reatment Course , Armstadt , Ermany , Md Serono , Ultiple Sclerosis , Reatment Naïve Patients , Linical Studies ,